{
  "docId": "019de074-6c10-759a-a503-c8b869115e9a",
  "docSlug": "3f9321c37d26dde2e5a75b53f195ef9c",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 31 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 31,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a three-column layout to summarize corporate actions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-6c10-759a-a503-c8b869115e9a/4",
  "deckHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a",
  "deckJsonHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json",
  "deckAnchorHref": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "list",
      "text": "Approved incremental $75M to existing $250M program initiated Sept’22, with goal to complete program by end of 2023. Repurchased $155M of stock to date, including $27M in 2023. $170M remains in capital return program; expected to complete by end of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a500ad3-dbb0-414b-8e51-20928aee193b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.36,
        "y": 0.32
      },
      "kind": "list",
      "text": "Prioritize resource allocation toward ampreloxetine Phase 3 study and YUPELRI® (revefenacin) PIFR-2 study. Discontinuing research activities, including stopping inhaled Janus kinase (JAK) inhibitor program. ~17% headcount reduction by end of Mar 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60810c1d-bb19-46c6-aa21-86a462eb2b67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.66,
        "y": 0.32
      },
      "kind": "list",
      "text": "Appointed independent director Susannah Gray to Board of Directors. Part of ongoing commitment to board refreshment. Lead Independent Director William D. Young will not stand for re-election at 2023 AGM. Company will put forth proposal to declassify the Board of Directors over time at 2023 AGM",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82d1a822-fdac-4557-b50c-0c03633f1e9b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.36,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Discontinuing Investments in Research",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2dbbe6dc-a461-4bdc-8e19-0debfc3f69b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.66,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Board and Governance Evolution",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ab925a8-88be-43a2-a28c-06a08e25fefd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.06,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Authorized $325M Capital Return Program",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce491d53-9557-4fec-8670-ba3671b8ed16",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "PIFR, peak inspiratory flow rate. AGM, Annual General Meeting – May 2, 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c43c5e9-d7df-42a5-9595-c0b6949f76c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Strategic Actions Focused on Continued Value Creation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d968b8cb-da3a-4b85-a80a-7979630c8ce8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "10b7d6da-0202-4ef1-bc86-a1a55be52a9d",
      "arcName": "The Transformation Tale",
      "arcSlug": "transformation-tale",
      "beatName": "Current Reality (Pain)",
      "beatSlug": "transformation-tale-current-reality-pain",
      "evidence": "Slides 1-5 set the stage for Theravance Biopharma's current state and challenges",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}